fda semaglutide warning news october 2025 U.S. | The FDA has approved a new higher dose (7.2 mg) of Wegovy ( semaglutide) injection, Wegovy HD, for weight loss and long-term weight Semaglutide Patient Safety Updates |

The compound was well tolerated with no evidence of genotoxicity, indicating its potential as a therapeutic agent for type 2 diabetes and obesity in humans

GLP-1 Receptor Agonists May Reduce Rheumatoid Arthritis Activity and Cardiovascular Risk in People with Obesity Key Takeaways: GLP-1 receptor agonists were linked to reduced rheumatoid arthritis (RA) disease activity and improved cardiovascular risk factors in people with obesity or overweight

Evidence supports increased light tolerance, fewer and less severe phototoxic reactions, and improved QoL in EPP, and it accelerates and augments repigmentation when added to NBUVB in vitiligo

The peptide has four amino acid substitutions in its structure, which scientists suggest may enhance its activity and resistance towards proteolytic enzymes